NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Akari Therapeutics (NASDAQ: AKTX) concerning possible violations of federal securities laws.
On April 26, 2017, Edison Research Ltd. issued a report on Akari called “Akari’s Coversin matches Soliris in Phase II.” The following day, it was announced the report had been withdraw due to “material inaccuracies.” Then on May 11, 2017, the Company announced that CEO Dr. Gur Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb had any involvement with the materially inaccurate research report. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.